Key Takeaways
- The most valuable healthcare company on earth reports in nine days: Eli Lilly (LLY) confirmed its third-quarter results for Thursday 29 October, with a call at 10am US Eastern. The stock has ground steadily higher into the print and sits within about 2% of its yearly high, carrying a market value above $1 TRILLION.
- The engine is obesity and diabetes medicine: Mounjaro and Zepbound demand has driven the story, and this month several banks lifted or reaffirmed price targets around $1,400-$1,440 (their estimates, not promises). Those two medicines alone made up about 65% of second-quarter revenue, which is the bull case and the concentration risk written as a single number.
- The newest trial data is extraordinary, and comes with a catch in the same sentence: Lilly's triple-hormone candidate EloraTZP delivered up to 23.3% average weight loss and a 2.9% drop in A1C over 48 weeks, beating its own component drugs, BUT with higher stomach-related side effects and more patients discontinuing treatment.
- And the company is widening beyond metabolics: the FDA cleared Jaypirca as a first-line option for certain untreated CLL/SLL patients, new oncology data went to the ESMO congress in October, the SHINE-2 study of Omvoh met its primary endpoint, and the Alzheimer's drug donanemab is moving into India.
- The honest catch: a stock priced for perfection turns small disappointments into large drops, side-effect discontinuations are a real commercial risk, Bloomberg reported hygiene problems at Chinese factories making GLP-1 components, and drug pricing sits permanently close to politics. LLY is an example to research, not a recommendation, and nothing here is medical advice.
- Research it your way: you can explore global stocks and ETFs from just $1 with zero commission on the Nemo.money app.
Introduction
The biggest company in healthcare isn't a hospital chain, an insurer or a vaccine maker. It's a 150-year-old drugmaker from Indianapolis whose market value has passed $1 TRILLION, and whose share price has been climbing, patiently and relentlessly, on the back of medicines that help people lose weight.
Eli Lilly (LLY) reports third-quarter results on Thursday 29 October, and it arrives at that date near its yearly high, with banks raising price targets toward $1,400 and a pipeline that keeps producing headlines. The latest: a triple-hormone candidate called EloraTZP that delivered up to 23.3% average weight loss over 48 weeks in trial data, with a meaningful drop in blood-sugar measures too, comfortably beating the individual drugs it combines.
It also came with more stomach-related side effects and more people stopping treatment, which is exactly the kind of detail that separates a research habit from a headline habit. Both facts are the story.
So this guide does three things. It explains how a pharmaceutical company became one of the most valuable businesses on the planet, it lays out what the 29 October report will actually test, and it unpacks the single most useful idea for anyone holding a market darling: what "priced for perfection" means, and why it cuts both ways.
One note before we start: this is an INVESTING article, not medical guidance. Nothing here is advice about any medicine, and decisions about treatments belong with a qualified doctor, not a finance blog.
It's educational, not investment advice. To explore, you can invest in global stocks and ETFs from just $1 with zero commission on the Nemo.money app.
People are searching:
- "Eli Lilly stock"
- "LLY earnings date"
- "Mounjaro Zepbound sales"
- "is Eli Lilly stock a buy"
- "biggest pharmaceutical company"
- "obesity drug stocks"
- "Eli Lilly price target"
Where the Company Stands Going In
- 🏆 A trillion-dollar drugmaker: Eli Lilly's (LLY) market value now exceeds $1 trillion, putting it in a club that until recently contained only technology companies, Apple (AAPL) crossed $5 trillion this month, and the fact that a medicine maker sits in the same conversation is itself the decade's quiet surprise.
- 📈 A grind, not a spike: the shares have climbed steadily rather than exploding, trading within roughly 2% of their yearly high going into the report. That matters for how results get received: a stock that has already risen on expectation needs results that BEAT the expectation, not merely meet it.
- 📅 The date is fixed: Lilly confirmed on 15 October that third-quarter results land on Thursday 29 October, with a conference call at 10:00am US Eastern. Pharma results rarely surprise on revenue alone; the guidance and the pipeline commentary usually move the price.
- 🏦 Wall Street has been raising its hand: through October, Cantor, Morgan Stanley, BMO, Berenberg, UBS, RBC and Barclays variously lifted or reaffirmed bullish ratings, with targets clustered around $1,400-$1,440 (their estimates, attributed, not promises, and price targets are opinions with a 12-month shelf life).
- ⚖️ And the inevitable counter-note: at least one widely read commentary this month argued the opposite case, that taking profits ahead of 2027 could make sense. Both views exist on every crowded trade; the honest catch below takes the bear case seriously.
The Engine, and the Pipeline Behind It
- 💉 Two medicines built the trillion: Mounjaro (for type 2 diabetes) and Zepbound (for weight management) turned a respected pharmaceutical company into a market phenomenon. Demand has consistently run ahead of expectations, which is why manufacturing capacity, not marketing, has been the recurring question on Lilly's calls. The scale is remarkable and so is the concentration: in the second quarter of 2026, Mounjaro brought in $9.94 billion and Zepbound $4.93 billion out of $23 billion of total revenue, about 65% of the company from two products.
- 🧪 The newest data, with both halves stated together: trial results for EloraTZP, a triple-hormone candidate, showed up to 23.3% average weight loss and a 2.9% reduction in A1C (a blood-sugar measure) over 48 weeks, outperforming the individual components it combines. The same results showed MORE stomach-related side effects and MORE patients discontinuing treatment than the comparators. In drug development, efficacy and tolerability are two scores on one report card, and commercial success needs both.
- 🎟️ The company is not a one-theme stock any more: the FDA cleared Jaypirca as a first-line option for certain untreated CLL/SLL patients (a blood-cancer indication), Lilly took new oncology data to the ESMO congress in late October, its SHINE-2 study of Omvoh met its primary endpoint, European regulators issued a positive opinion on another product, and its Alzheimer's drug donanemab is moving into India, a market of enormous scale.
- 🤝 And it keeps buying optionality: October also brought a clinical-trial collaboration and supply agreement with a smaller biotech partner, the kind of low-cost, high-option deal big pharma uses to rent innovation rather than build it.
- 🧭 The investor's read: a company with ONE blockbuster is a bet on that blockbuster. A company with a blockbuster plus a deep, diversified late-stage pipeline is a bet on a research ENGINE, which is a different, and usually more durable, proposition. The 29 October call is where you check whether the engine is still humming.
Why the Demand Story Keeps Widening
- 🏢 Employers are starting to pay: Walmart (WMT) said in October it will cover some GLP-1 medicines, inhalers and insulin for its employees at no cost. When one of the world's largest private employers makes a category free at the point of use, it signals a shift from "patients who can afford it" toward "patients whose plan includes it", and payer coverage is the single biggest swing factor in how large these markets ultimately become.
- 🔬 The next generation is already in flight: both Lilly and its chief rival are developing amylin-based medicines as the successors to today's GLP-1 drugs. The competitive question for the 2030s isn't whether obesity medicine is big, it's who owns the molecules that follow.
- 🌍 The access angle for our readers: these medicines have become a global phenomenon, with demand across the Gulf and South Asia well documented, and Lilly's Alzheimer's treatment now moving into India. Availability, pricing and regulatory approval differ enormously by country, which is a medical and regulatory matter for local doctors and authorities, not an investing one, but for the COMPANY, every new market is incremental revenue with its own approval timeline.
- 💰 What it adds up to commercially: a category with expanding coverage, expanding geography and a visible successor generation is the rare combination that justifies a premium multiple. The debate isn't whether the demand is real; it's how much of the next decade's demand is already in today's price, which is where the teachable below comes in.
The Teachable: What "Priced for Perfection" Really Means
- 🏷️ The phrase has a precise meaning: a stock is priced for perfection when its valuation already assumes years of things going right, strong launches, no manufacturing stumbles, no competitive surprises, supportive regulation. Nothing is wrong with that; it's what premium valuations ARE. The consequence is mechanical: when expectations are perfect, merely GOOD news is a disappointment.
- 🧮 Why the drops are violent when they come: if a price embeds a decade of growth, a single quarter that trims the growth assumption takes out several years of value at once. That's why market darlings fall further on mild misses than ordinary companies fall on bad ones, and why the phrase "it's a great company" never answers the question "is it a good price?".
- 🔄 The live case study sits right next door: Lilly's chief rival in obesity medicine, Novo Nordisk (NVO), spent years as Europe's most valuable company before trial disappointments and competitive pressure reset its story, with coverage this month describing its continuing struggles and noting that pharma is an impatient market. Same category, same boom, very different year. Leadership in a two-horse race is not a permanent condition.
- 🧰 The practical habit: for any premium stock, write down what you think is already priced IN before results, then compare the report to your own list rather than to the headline reaction. Our guide to reading an earnings report walks through exactly where to look. And hold the reverse case alongside it: healthcare fortunes swing both ways, as UnitedHealth's collapse-and-comeback showed this year, and as Moderna's return to the Nasdaq-100 after a 650% comeback year showed even more dramatically. Today's priced-for-perfection winner and yesterday's left-for-dead laggard are often the same sector, a few years apart.
What 29 October Will Actually Test
- 📊 Test one, the growth rate AND the price: Mounjaro and Zepbound revenue, whether growth is still ACCELERATING or merely large, and critically the split between volume and price. In the second quarter, volumes rose about 60% while realised prices fell about 13%, so the live question each quarter is whether volume keeps outrunning discounting. For a premium-priced company, that second derivative matters more than the headline number.
- 🔮 Test two, the guidance: what management says about the rest of this year and its early framing of next. In pharma, guidance revisions move stocks far more than the quarter just gone.
- 🏭 Test three, supply: manufacturing capacity has been the recurring constraint of this entire boom. Any commentary on plants, output and the ability to meet demand goes straight to the revenue model.
- 🧪 Test four, the pipeline calendar: timelines for the triple-hormone programme, amylin candidates, and the non-metabolic franchises (oncology, immunology, Alzheimer's). Dates slipping is how expensive stories get repriced quietly.
- 🧭 And the discipline to bring: decide BEFORE the call what would count as good enough on each of those four, then grade the report against your list, not the after-hours price. Pre-registering your criteria is the cheapest defence against being whipsawed by a headline.
The Honest Catch
- 💸 The valuation is the headline risk: above $1 trillion and near its high, Lilly (LLY) carries expectations that leave little room for stumbles. The bullish targets around $1,400-$1,440 are analyst opinions; a commentary this month arguing for taking profits ahead of 2027 is equally an opinion. Price is where those opinions collide.
- 🤢 Tolerability is a commercial issue, not just a clinical one: the newest trial's stronger results came with more gastrointestinal side effects and more discontinuations. Patients who stop taking a medicine stop buying it, so side-effect profiles feed directly into revenue durability, which is why analysts read those tables as closely as the efficacy numbers.
- 🏭 Supply chains carry headline risk: Bloomberg reported in October that Chinese factories producing components used in GLP-1 medicines had hygiene problems including mould and insects. That is a reported supply-chain story, not a claim about any specific finished product, but it illustrates how a global manufacturing web can generate reputational and regulatory risk far from headquarters.
- 🏛️ Drug pricing lives next to politics: governments, insurers and employers are all negotiating what these medicines should cost, and pricing pressure is the permanent weather of the pharmaceutical industry. Coverage expansion (good for volume) and price concessions (bad for margin) usually arrive together, and the discounting war with Novo Nordisk (NVO) is already visible in the reported numbers: Lilly's realised prices fell around 13% year on year last quarter even as volumes surged, and Novo has attributed much of its own shortfall to pricing pressure. A price war in a two-player market is the fastest way for a booming category to become a less profitable one.
- ⏳ And nothing lasts forever: patents expire, rivals iterate, and the next generation of medicines, including the ones Lilly itself is developing, eventually competes with today's winners. LLY, NVO and WMT are examples to research, not recommendations, and nothing in this article is medical advice.
What It Means for You
- 🧭 Separate the company from the price: "the best drug pipeline in the industry" and "a sensible price today" are two different judgements, and only the second one determines your return from here.
- 📅 Mark the date and pre-register your criteria: 29 October, after the US close, with the call at 10am Eastern the same morning for the results release timing. Write your pass/fail marks for growth, guidance, supply and pipeline before the numbers land.
- 🪞 Check what you already own: at this size, Lilly is a top-weight holding in most global and US healthcare funds, so index investors already hold a slice of this story whether or not they ever researched it.
- 🧪 And keep the two-sided habit: every statistic in this story has a second half, 23.3% weight loss AND more discontinuations, expanding coverage AND pricing pressure, a trillion-dollar valuation AND a rival that was Europe's most valuable company not long ago.
How to Research This with Nemo.money
The Nemo.money app is built to help you research before you decide:
- Invest from Just $1: Fractional investing means a four-figure share price doesn't put a company out of research reach.
- Zero-Commission Trading: Buy and sell US-market stocks and ETFs without commission fees.
- AI-Powered Insights & Nemes: Explore data, sentiment and curated themed collections (Nemes) as a research starting point (for research, not recommendations).
- Earn 6% AER on Idle Cash: Uninvested cash in your wallet earns 6% AER, paid daily in USD while you wait for the numbers.
Frequently Asked Questions (FAQs)
When does Eli Lilly report earnings?
Eli Lilly (LLY) confirmed on 15 October 2026 that it will announce third-quarter 2026 results on Thursday 29 October 2026, with a conference call at 10:00am US Eastern time. This is general information, not advice.
Why is Eli Lilly stock so high?
The company's medicines for type 2 diabetes and weight management, Mounjaro and Zepbound, have driven exceptional demand growth, and its pipeline has continued to produce positive data across metabolic, oncology and immunology programmes. Its market value now exceeds $1 trillion, and several banks raised or reaffirmed price targets around $1,400-$1,440 in October (their estimates, not promises). This is general information, not advice.
What is EloraTZP?
It is Lilly's triple-hormone investigational treatment. Trial data reported in October showed up to 23.3% average weight loss and a 2.9% reduction in A1C over 48 weeks, outperforming its component drugs, alongside higher rates of stomach-related side effects and more patients discontinuing treatment. This is general information about a company's clinical data, not medical advice; treatment decisions belong with a qualified doctor.
Who is Eli Lilly's main competitor?
Novo Nordisk (NVO), maker of rival weight-management and diabetes medicines, is the principal competitor. Once Europe's most valuable company, it has faced trial disappointments and competitive pressure, a reminder that leadership in this category has already changed hands once. This is general information, not advice.
Can I invest in Eli Lilly from the UAE?
Eli Lilly trades on the New York Stock Exchange under the ticker LLY. On the Nemo.money app you can research and invest in eligible US-listed stocks and ETFs from $1 with zero commission (subject to availability), with uninvested cash earning 6% AER, paid daily in USD. LLY is an example to research, not a recommendation, and your capital is at risk.
Final Thoughts: The Quietest Trillion in the Market
While the market spent this month arguing about artificial intelligence, a 150-year-old medicine company passed a trillion dollars in value by doing something unglamorous: selling products people want, faster than it can make them. No launch events, no app-store crowns, just demand.
That's what makes Lilly such a useful stock to study even if you never buy a share. It shows that the market's biggest stories aren't always the loudest ones. It shows how a premium valuation works, as a compliment that doubles as a hurdle. And it shows, through its own rival's reversal, how quickly a category's champion can become its cautionary tale.
Nine days from now, the scoreboard updates. Growth, guidance, supply, pipeline. Decide what good looks like before the numbers arrive, and let the report, not the reaction, tell you whether the trillion was earned.
Explore global stocks and ETFs from $1 with zero commission on the Nemo.money app.
Nemo = Never Miss Out.
Stay informed. Stay ahead.
#EliLilly #LLY #Pharma #ObesityDrugs #Earnings #StockMarket #Investing #NemoMoney
Terms and conditions apply. This is not investment advice and not medical advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.
